Lantern Pharma has received FDA clearance for its Investigational New Drug (IND) application for LP-184 to treat Triple-Negative Breast Cancer (TNBC). This approval targets a critical area, as TNBC represents a significant global disease burden with an estimated $3-5 billion market opportunity and a grim median survival of only 10 to 18 months for newly diagnosed metastatic patients.
